| 3.08 0.56 (22.22%) | 11-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.76 | 1-year : | 4.39 |
| Resists | First : | 3.22 | Second : | 3.76 |
| Pivot price | 2.01  |
|||
| Supports | First : | 2.24 | Second : | 1.63 |
| MAs | MA(5) : | 2.42 |
MA(20) : | 1.96 |
| MA(100) : | 1.96 |
MA(250) : | 2.58  |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 77.9 |
D(3) : | 77.7 |
| RSI | RSI(14): 85.9 |
|||
| 52-week | High : | 4.17 | Low : | 1.48 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ WALD ] has closed above the upper band by 23.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 177.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.15 - 3.16 | 3.16 - 3.17 |
| Low: | 2.4 - 2.41 | 2.41 - 2.42 |
| Close: | 3.06 - 3.08 | 3.08 - 3.1 |
Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.
Fri, 21 Nov 2025
Earnings To Watch: Waldencast PLC (WALD) Reports Q2 2025 Result - Yahoo Finance
Fri, 14 Nov 2025
Waldencast plc Sells Obagi Trademark Rights in Japan to Rohto Pharmaceutical for $82.5 Million - Quiver Quantitative
Fri, 14 Nov 2025
Waldencast (NASDAQ: WALD) sells Japan Obagi trademark for $82.5M, enters $225M term loan - Stock Titan
Fri, 14 Nov 2025
WALD SEC Filings - Waldencast plc 10-K, 10-Q, 8-K Forms - Stock Titan
Wed, 12 Nov 2025
Waldencast (NASDAQ: WALD) sets Nov. 24 for second and third quarter 2025; no call - Stock Titan
Fri, 07 Nov 2025
Waldencast PLC expected to post a loss of 7 cents a share - Earnings Preview - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Technology
|
|
|
Industry:
Software - Application
|
|
| Shares Out | 113 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 57 (%) |
| Held by Institutions | 26.4 (%) |
| Shares Short | 682 (K) |
| Shares Short P.Month | 988 (K) |
| EPS | -0.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.9 |
| Profit Margin | -15.5 % |
| Operating Margin | -18.4 % |
| Return on Assets (ttm) | -3.4 % |
| Return on Equity (ttm) | -6.5 % |
| Qtrly Rev. Growth | 30.7 % |
| Gross Profit (p.s.) | 1.7 |
| Sales Per Share | 2.43 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | 8 (M) |
| PE Ratio | -7.9 |
| PEG Ratio | 0 |
| Price to Book value | 0.52 |
| Price to Sales | 1.26 |
| Price to Cash Flow | -39.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|